Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4098661 | 0.98 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| Cyclohexane SCHEMBL8585009 | 0.95 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| Glycine SCHEMBL7359841 | 0.92 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| Glycine SCHEMBL8008693 | 0.91 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL11684413 | 0.87 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPK1KMT2ACYP1A2 | |
| SCHEMBL14416429 | 0.86 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| SCHEMBL26571803 | 0.86 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| SCHEMBL7695939 | 0.85 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| SCHEMBL5615956 | 0.83 | NPC1 (0.46) | ALDH1A1L3MBTL1MAPK1KMT2ACYP1A2 | |
| SCHEMBL4935091 | 0.83 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979658-B | Preparation method of flumazenil | 南湖实验室 | 2022-05-31 | — | — | CN | claimed |
| EP-2115140-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF 1H-IMIDAZO [4, 5-C] QUINOLIN-4-AMINES AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | Yu, Chongxi (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008093173-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF 1H-IMIDAZO[4, 5-C]QUINOLIN-4-AMINES AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | YU CHONGXI (US) | 2008-08-07 | — | — | WO | claimed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4608452-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250092392-A1 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-0448343-A2 | Lipopeptide derivatives | MERCK & CO. INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0448354-A2 | Lipopeptide derivatives | MERCK & CO. INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| US-5047519-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-09-10 | — | — | US | disclosed |
| US-4988681-A | Dipeptidase inhibitore; reducing renal toxicity; prevention deactivation of (carba)penem antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| EP-0347840-A2 | Phosphinic acid derivates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0309969-A2 | Method of gene mapping | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0252683-A2 | Process and reagents for DNA sequence analysis | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
| EP-0251786-A2 | Alkynylamino-nucleotides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| US-4028319-A | 2 AND 3-SUBSTITUTED ENKEPHALINS | G. D. SEARLE & CO. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885L3MBTL1 3097/4885MAPK1 352/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | ALDH1A1 4135/4885L3MBTL1 819/4885MAPK1 202/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ALDH1A1 4101/4885L3MBTL1 472/4885MAPK1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.